Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron-Reference-Cited by-同舟云学术

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

Published:2022-06-23 Issue:25 Volume:386 Page:2433-2435
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Accorsi Emma K.¹,Britton Amadea¹,Shang Nong¹,Fleming-Dutra Katherine E.¹,Link-Gelles Ruth¹,Smith Zachary R.¹,Derado Gordana¹,Miller Joseph¹,Schrag Stephanie J.¹,Verani Jennifer R.¹

Affiliation:

1. Centers for Disease Control and Prevention, Atlanta, GA

Funder

Centers for Disease Control and Prevention

U.S. Department of Health and Human Services

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2203165

Reference3 articles.

1. Homologous and Heterologous Covid-19 Booster Vaccinations

2. Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans

3. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing;International Journal of Biological Macromolecules;2024-10

2. Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron;Journal of Infection;2024-06

3. Description of Clinical Outcomes of Janssen’s Ad26.COV2.S Prime and Single Boost for COVID-19 from January 2021 through July 2022 at a large Kentucky study site;Norton Healthcare Medical Journal;2024-05-16

4. SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR;2024-05-14

5. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants;PLOS Global Public Health;2024-04-11